About Mestag Therapeutics

Mestag develops first-in-class antibody therapies targeting fibroblast immunology to treat cancer and inflammatory diseases. The company focuses on patients who do not respond to current treatments, where 50 to 70 percent of cancer patients and 60 percent of inflammatory disease patients fail to achieve lasting remission. By redirecting fibroblast interactions with the immune system, Mestag restores immune function. The lead programme, MST-0312, induces tertiary lymphoid structures in solid tumours. The M402 programme targets diseases including rheumatoid arthritis and lupus by dampening overactive immune cells. Backed by leading investors and scientific founders, Mestag is advancing rapidly towards clinical trials.